Novo Nordisk's Experimental CagriSema (Cagrilintide Plus Semaglutide Fixed-Dose Combination, Regulatory Filing Submitted December 18, 2025 With Expected FDA Decision Late 2026) Reportedly Failed to Control Blood Sugar as Effectively as Eli Lilly's Tirzepatide (Mounjaro/Zepbound) in a Head-to-Head Phase 3 Trial of Patients With Type 2 Diabetes; The Trial Outcome Contributes to the Widening Lilly-Novo Franchise Gap Documented Across the Q2 2026 Earnings Week With Lilly Q2 Revenue at $23 Billion (+48% YoY) and Novo H1 at 78.49 Billion DKK ($12.09 Billion, +3% Constant Currency With 5% Stock Decline) as the Investor Narrative on Novo's Ability to Defend GLP-1 Franchise Economics Continues to Deteriorate
Novo Nordisk's experimental CagriSema (cagrilintide plus semaglutide fixed-dose combination) reportedly failed to control blood sugar as effectively as Eli Lilly's tirzepatide (Mounjaro/Zepbound) in a head-to-head Phase 3 trial of patients with type 2 diabetes. CagriSema regulatory filing was submitted December 18, 2025 with an expected FDA decision in late 2026 for obesity indication; the type 2 diabetes head-to-head failure complicates the commercial narrative and label-expansion strategy. The trial outcome adds to the widening Lilly-Novo franchise gap documented across the Q2 2026 earnings week: Eli Lilly (NYSE: LLY) Q2 revenue reached $23 billion (+48% year-over-year) with Foundayo (orforglipron oral small-molecule GLP-1) delivering $98 million in its first fully operational commercial quarter and Mounjaro + Zepbound combined at $14.9 billion; Novo Nordisk H1 2026 sales reached 78.49 billion Danish kroner ($12.09 billion, +3% constant currency) with shares declining 5% on margin-compression concerns despite raised guidance. Investor narrative on Novo's ability to defend GLP-1 franchise economics continues to deteriorate as the amylin analog (cagrilintide) that Novo positioned as its differentiator against tirzepatide's dual GIP/GLP-1 mechanism failed to close the efficacy gap in the head-to-head setting.